South Korean medical AI company AIRS Medical has won expanded U.S. FDA 510(k) clearance for SwiftMR, its deep-learning MRI image enhancement platform, the company confirmed. The new label allows SwiftMR to be deployed alongside original equipment manufacturer deep-learning reconstruction modalities — a first for the product.
The expanded clearance comes as U.S. radiology departments accelerate adoption of AI tools to relieve growing scanner backlogs. By the start of 2026, the FDA had authorized 950 AI/ML devices, 723 of them in radiology, and SwiftMR has been one of the most widely deployed software-only entrants in the category.
What the clearance unlocks
Previously, SwiftMR had to be applied as a standalone enhancement layer on conventionally reconstructed MRI scans. With the expanded label, the software can also be used downstream of OEM deep-learning reconstruction pipelines from major scanner vendors, allowing hospitals to combine vendor and third-party AI without compliance ambiguity.
Why it matters
For imaging centers, the result is faster scans at preserved diagnostic quality without buying new hardware. AIRS estimates SwiftMR can cut scan times by up to half, an attractive proposition for U.S. networks struggling with capacity and wait lists for MRI appointments. The clearance also strengthens AIRS Medical's positioning ahead of EU AI Act compliance requirements for high-risk radiology AI.
Competitive landscape
SwiftMR competes against in-house tools from Siemens Healthineers, GE HealthCare and Philips, as well as a thickening cohort of software-only entrants. AIRS' bet is that vendor-agnostic AI will appeal to multi-vendor health systems that don't want to be locked into a single scanner OEM's reconstruction stack.
Outlook
Expanding into OEM deep-learning reconstruction workflows positions AIRS Medical to be embedded deeper inside hospital MRI operations. Investors will watch whether the company can convert its expanding regulatory footprint into U.S. revenue ahead of an expected public listing.
Reporting based on coverage from Diagnostic Imaging and Intuition Labs analyses.